Copyright Reports & Markets. All rights reserved.

Global Metachromatic Leukodystrophy (MLD) Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Metachromatic Leukodystrophy (MLD) Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Product
      • 1.4.2 AGT-183
      • 1.4.3 DUOC-01
      • 1.4.4 GSK-2696274
      • 1.4.5 Others
    • 1.5 Market by End User
      • 1.5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size
      • 2.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue 2014-2025
      • 2.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales 2014-2025
    • 2.2 Metachromatic Leukodystrophy (MLD) Treatment Growth Rate by Regions
      • 2.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Regions
      • 2.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers
      • 3.1.1 Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers
      • 3.1.2 Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Metachromatic Leukodystrophy (MLD) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers
      • 3.2.1 Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Metachromatic Leukodystrophy (MLD) Treatment Price by Manufacturers
    • 3.4 Metachromatic Leukodystrophy (MLD) Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Metachromatic Leukodystrophy (MLD) Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Metachromatic Leukodystrophy (MLD) Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Product
    • 4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Product
    • 4.3 Metachromatic Leukodystrophy (MLD) Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Metachromatic Leukodystrophy (MLD) Treatment by Countries
      • 6.1.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Countries
      • 6.1.2 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Metachromatic Leukodystrophy (MLD) Treatment by Product
    • 6.3 North America Metachromatic Leukodystrophy (MLD) Treatment by End User

    7 Europe

    • 7.1 Europe Metachromatic Leukodystrophy (MLD) Treatment by Countries
      • 7.1.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Countries
      • 7.1.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Metachromatic Leukodystrophy (MLD) Treatment by Product
    • 7.3 Europe Metachromatic Leukodystrophy (MLD) Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment by Countries
      • 8.1.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Countries
      • 8.1.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment by Product
    • 8.3 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Metachromatic Leukodystrophy (MLD) Treatment by Countries
      • 9.1.1 Central & South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Countries
      • 9.1.2 Central & South America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Metachromatic Leukodystrophy (MLD) Treatment by Product
    • 9.3 Central & South America Metachromatic Leukodystrophy (MLD) Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment by Countries
      • 10.1.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment by Product
    • 10.3 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment by End User

    11 Company Profiles

    • 11.1 ArmaGen Inc
      • 11.1.1 ArmaGen Inc Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Products Offered
      • 11.1.5 ArmaGen Inc Recent Development
    • 11.2 GlaxoSmithKline Plc
      • 11.2.1 GlaxoSmithKline Plc Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Products Offered
      • 11.2.5 GlaxoSmithKline Plc Recent Development
    • 11.3 Recursion Pharmaceuticals Inc
      • 11.3.1 Recursion Pharmaceuticals Inc Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Products Offered
      • 11.3.5 Recursion Pharmaceuticals Inc Recent Development
    • 11.4 RegenxBio Inc
      • 11.4.1 RegenxBio Inc Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Products Offered
      • 11.4.5 RegenxBio Inc Recent Development
    • 11.5 Shire Plc
      • 11.5.1 Shire Plc Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Shire Plc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Shire Plc Metachromatic Leukodystrophy (MLD) Treatment Products Offered
      • 11.5.5 Shire Plc Recent Development

    12 Future Forecast

    • 12.1 Metachromatic Leukodystrophy (MLD) Treatment Market Forecast by Regions
      • 12.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Metachromatic Leukodystrophy (MLD) Treatment Market Forecast by Product
      • 12.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Metachromatic Leukodystrophy (MLD) Treatment Market Forecast by End User
    • 12.4 North America Metachromatic Leukodystrophy (MLD) Treatment Forecast
    • 12.5 Europe Metachromatic Leukodystrophy (MLD) Treatment Forecast
    • 12.6 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Forecast
    • 12.7 Central & South America Metachromatic Leukodystrophy (MLD) Treatment Forecast
    • 12.8 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Metachromatic Leukodystrophy (MLD) Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Metachromatic Leukodystrophy (MLD) Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Metachromatic Leukodystrophy (MLD) Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Metachromatic Leukodystrophy (MLD) Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Metachromatic Leukodystrophy (MLD) Treatment in these regions.
      This research report categorizes the global Metachromatic Leukodystrophy (MLD) Treatment market by top players/brands, region, type and end user. This report also studies the global Metachromatic Leukodystrophy (MLD) Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      ArmaGen Inc
      GlaxoSmithKline Plc
      Recursion Pharmaceuticals Inc
      RegenxBio Inc
      Shire Plc

      Market size by Product
      AGT-183
      DUOC-01
      GSK-2696274
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Metachromatic Leukodystrophy (MLD) Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Metachromatic Leukodystrophy (MLD) Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Metachromatic Leukodystrophy (MLD) Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Metachromatic Leukodystrophy (MLD) Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Metachromatic Leukodystrophy (MLD) Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Metachromatic Leukodystrophy (MLD) Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now